"From clinical point of view, therapy with clinically available TZDs (pioglitazone or rosiglitazone) may raise some doubts. Rosiglitazone has been withdrawn from European market (although it is still available in the United States) because of reports on increased cardiovascular risk, whereas pioglitazone has been correlated with increased risk of bladder cancer. On the other hand, these potential adverse effects are still not unambiguously confirmed and were observed only after long-time treatment. The benefit of such treatment in patients with leukemia can overweight potential risk, and therefore the use of TZDs (including withdrawn troglitazone) can be justified. Moreover, pioglitazone is known to reduce cardiovascular risk in various clinical settings and is currently tested for secondary prevention after ischemic stroke in patients with diabetes.8 This protective effect might be beneficial in relation to the risk of serious cardiovascular side effects of TKIs".
Extract from PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells